These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2207342)

  • 1. Treatment of refractory multiple myeloma with the vincristine-adriamycin-dexamethasone (VAD) regimen.
    Stenzinger W; Blömker A; Hiddemann W; van de Loo J
    Blut; 1990; 61(2-3):55-9. PubMed ID: 2207342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group.
    Browman GP; Belch A; Skillings J; Wilson K; Bergsagel D; Johnston D; Pater JL
    Br J Haematol; 1992 Nov; 82(3):555-9. PubMed ID: 1486035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study.
    Gertz MA; Kalish LA; Kyle RA; Hahn RG; Tormey DC; Oken MM
    Am J Clin Oncol; 1995 Dec; 18(6):475-80. PubMed ID: 8526187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VAD chemotherapy for refractory multiple myeloma.
    Lokhorst HM; Meuwissen OJ; Bast EJ; Dekker AW
    Br J Haematol; 1989 Jan; 71(1):25-30. PubMed ID: 2644970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of refractory multiple myeloma with vincristine, adriamycin, dexamethasone, and with repeated application of cyclophosphamide (C-VAD).
    Adam Z; Elbl L; Vorlicek J; Hájek R; Hájek D; Hejlová N; Králová E; Novotná H
    Acta Med Austriaca; 1994; 21(4):111-5. PubMed ID: 7871966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bolus vincristine and epirubicin with cyclophosphamide and dexamethasone (VECD) as induction and salvage treatment in multiple myeloma.
    Fosså A; Muer M; Kasper C; Welt A; Seeber S; Nowrousian MR
    Leukemia; 1998 Mar; 12(3):422-6. PubMed ID: 9529138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [VAD chemotherapy of multiple myeloma].
    Amano M; Itoh K; Togawa A
    Rinsho Ketsueki; 1990 Jul; 31(7):917-21. PubMed ID: 2214189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of refractory multiple myeloma with vincristine, adriamycin, and dexamethasone].
    Ma MX; Yiu JR; Wu SL
    Zhonghua Nei Ke Za Zhi; 1989 May; 28(5):267-9, 313. PubMed ID: 2805963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VAD protocol for treatment of advanced refractory multiple myeloma.
    Scheithauer W; Cortelezzi A; Kutzmits R; Baldini L; Ludwig H
    Blut; 1987 Sep; 55(3):145-52. PubMed ID: 3620710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose glucocorticoid treatment of resistant myeloma.
    Alexanian R; Barlogie B; Dixon D
    Ann Intern Med; 1986 Jul; 105(1):8-11. PubMed ID: 3717812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etoposide and ifosfamide for MP (melphalan and prednisolone)- and VAD (vincristine, adriamycin and dexamethasone)-resistant plasma cell myeloma: a case report.
    Ikeda K; Abe N; Morioka A; Inoo M; Nagai M; Kubota Y; Irino S
    Jpn J Med; 1990; 29(5):516-8. PubMed ID: 2089176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol.
    Giles FJ; Wickham NR; Rapoport BL; Somlo G; Lim SW; Shan J; Lynott AM
    Am J Hematol; 2000 Mar; 63(3):125-30. PubMed ID: 10679801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
    Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
    Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [VAD regimen for multiple myeloma--the effectiveness as first line therapy].
    Fujii Y; Nisimura Y; Tanizawa Y; Azuno Y; Yaga K; Hirosige Y; Kaku K; Kaneko T; Matumoto N
    Rinsho Ketsueki; 1991 Mar; 32(3):280-2. PubMed ID: 2041172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma.
    Dimopoulos MA; Pouli A; Zervas K; Grigoraki V; Symeonidis A; Repoussis P; Mitsouli C; Papanastasiou C; Margaritis D; Tokmaktsis A; Katodritou I; Kokkini G; Terpos E; Vyniou N; Tzilianos M; Chatzivassili A; Kyrtsonis MC; Panayiotidis P; Maniatis A;
    Ann Oncol; 2003 Jul; 14(7):1039-44. PubMed ID: 12853344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermediate dose of intravenous melphalan in advanced multiple myeloma.
    Tsakanikas S; Papanastasiou K; Stamatelou M; Maniatis A
    Oncology; 1991; 48(5):369-71. PubMed ID: 1745483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
    Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
    Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lower cardiotoxicity of adriamycin during continuous administration in patients with refractory multiple myeloma treated with cyclophosphamide, vincristine, adriamycin and dexamethasone (C-VAD)].
    Adam Z; Elbl L; Vorlícek J; Hájek R; Tomíska M; Hejlová N; Králová E; Novotná H
    Vnitr Lek; 1994 Aug; 40(8):506-12. PubMed ID: 7941437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative evaluation of treatment results in advanced multiple myeloma with the help of polychemotherapy with vincristine, doxorubicin, dexamethasone (VAD) or only with dexamethasone].
    Hansz J; Włodarczyk M; Psuja P
    Acta Haematol Pol; 1992; 23(4):277-84. PubMed ID: 1293910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.